Gene therapy legislation in The Netherlands.

Area of Science:

• Biotechnology and Regulatory Science
• Environmental Risk Assessment
• Clinical Gene Therapy

Background:

• Clinical gene therapy trials in The Netherlands involve multiple regulatory bodies.
• The Central Committee on Research Involving Human Subjects (CCMO) assesses medical, ethical, and scientific aspects.
• The Ministry of Housing, Spatial Planning and the Environment (VROM) handles environmental risk assessment.

Purpose of the Study:

• To review gene therapy legislation in The Netherlands.
• To explain The Netherlands' rationale for using Directive 2001/18/EC for environmental risk assessment.
• To highlight the need for harmonisation of EU member states' approaches to gene therapy trial assessment.

Main Methods:

• Review of national legislation and EU directives concerning gene therapy.
• Analysis of the regulatory framework for genetically modified organisms (GMOs) in clinical trials.
• Examination of the role and impact of the Gene Therapy Office.

Main Results:

• A Gene Therapy Office has been established to expedite national review processes.
• The Netherlands applies Directive 2001/18/EC for the environmental risk assessment of gene therapy trials.
• Discrepancies exist among EU member states regarding the governing directive for gene therapy assessments.

Conclusions:

• The Netherlands has a structured approach to gene therapy trial regulation, including environmental risk assessment.
• The current divergence in EU member states' regulatory approaches necessitates harmonisation for efficient clinical trial progression.